Cross Country Healthcare announced on May 8, 2026 that it has agreed to be acquired by private equity firm Knox Lane in an all-cash deal valued at $437 million — $13.25 per share, a 31% premium over its closing price the day before the announcement. The deal is expected to close in Q3 2026 pending regulatory approval.

If the name Knox Lane doesn't register: they run a $3.5 billion PE portfolio with existing healthcare staffing holdings including All Star Healthcare and HCEsquared. This is their play for a bigger slice of the healthcare workforce market at a moment when travel nurse demand has normalized significantly off COVID-era peaks.

How We Got Here: The FTC Killed the Aya Deal First

This acquisition comes after Cross Country's proposed $615 million merger with Aya Healthcare collapsed in December 2025. The FTC blocked that deal, citing "significant competitive concerns" about what would have been a combination of two of the largest travel nurse staffing platforms in the country. The agency's worry: too much consolidated pricing power in healthcare labor markets where hospitals are already structurally dependent on agencies.

With the Aya deal dead, Cross Country came to market at a lower valuation. Q1 2026 revenue was $241.1 million — down 18% year-over-year — and the company posted a $4.3 million net loss. The travel nurse staffing market has been contracting since the pandemic-era premium rates ended, and Cross Country's financials reflect exactly that normalization.

What Cross Country Does

Cross Country places travel nurses, allied health professionals, and locum physicians across hospital systems and healthcare networks nationwide. Its technology platform, Intellify, integrates with hospital workforce management systems for demand forecasting and labor utilization. The company also provides workforce advisory services — essentially consulting for hospital systems trying to reduce their dependence on expensive travel contracts while still having access to them when census spikes.

If you've taken a Cross Country contract recently, you've been in this ecosystem. The Intellify platform is what recruiters use to match clinicians to facilities. It also powers some of the vendor-neutral managed service programs (MSPs) that large hospital systems use to centralize agency procurement.

What This Means for Travel Nurses

Private equity ownership of a travel nursing agency is not inherently good or bad for nurses — but the incentive structure shifts. PE firms optimize for EBITDA margins over a 3-5 year hold period. In practice that has historically meant cost reduction in recruiting, customer service, and benefit administration rather than rate compression for clinicians directly. Clinician rates are the product; agencies don't cut rates to nurses the way they might cut back-office headcount.

The bigger concern is consolidation itself. The FTC killed the Aya merger for a reason: fewer major agencies means less competitive pressure on markup rates charged to hospitals, which can indirectly suppress the pool of money available for clinician pay. The Knox Lane deal doesn't create the same market-concentration issue the Aya merger would have, but it continues a trend of PE roll-ups in travel staffing that reduces the number of truly independent agencies competing for nurse placements.

What you can do as a travel nurse: work with multiple agencies simultaneously. You are not obligated to exclusivity. Cross Country, Aya, AMN, TotalMed, Travel Nurse Across America, and dozens of smaller specialty agencies all post different contracts and pay different bill rates from the same hospitals. Running multiple recruiters is the only way to actually benchmark what a given contract is paying versus what it could be.

Use the stipend calculator to model total package comparisons across agency offers — the posted hourly rate is only part of the number.

The Bigger Picture: Travel Staffing Is Consolidating

The Cross Country-Knox Lane deal is one chapter in a longer story about what happens to the travel nursing market after the pandemic-era boom. At peak COVID demand (2021-2022), travel RN weekly rates regularly hit $5,000-$8,000. That market is gone. Normalized demand means agencies are competing on margins that weren't possible when hospitals were paying anything to fill shifts. Consolidation is the predictable response: scale reduces costs, and PE firms have been circling the sector for exactly this reason. What nurses need to understand is that this is a structural shift in an industry that directly affects your income, not a passive financial transaction happening somewhere above your pay grade.